Microscopic crystals (microcrystals) within articular and periarticular tissues are among the most common causes of acute mono/polyarthritis and, less frequently, chronic arthritis. The two most common types of microcrystal synovitis are those associated with:
• monosodium urate monohydrate (MSUM): gout
• calcium pyrophosphate dihydrate (CPPD): pseudogout. These arthritides are frequently encountered in medical inpatients in whom intercurrent illness and dehydration may trigger attacks. Other rarer forms of microcrystal arthritis are also recognised (oxalate and hydroxyapatite) but are beyond the scope of this article.
Gout

Introduction and clinical features
Hippocrates described acute gout in the 4th century BC. Dr Thomas Sydenham's classic description in the 17th century illustrates the typical clinical features (Box 1).
Gout, a common condition affecting approximately 1% of men in the UK, is a metabolic disorder characterised by chronic hyperuricaemia (uric acid serum concentrations >0.45 mmol/l). Uric acid is produced endogenously during purine metabolism and also ingested in purine rich food and drink (particularly red meat, seafood and alcohol); 1 it is excreted via the kidneys. Causes of chronic hyperuricaemia are shown in Table 1 . Insulin resistance may be an important contributor to the pathogenesis of gout, since elevated insulin decreases renal excretion of uric acid. 2 Chronic elevation of serum uric acid allows the formation of MSUM microcrystals within the synovium, articular cartilage, skin and tendons. These microcrystals can trigger a significant monocyte-driven, neutrophil-mediated acute synovitis or tenosynovitis. 3 Acute attacks of gout most commonly involve a single joint and affect men more frequently than women (the first attack usually occurring between 40 and 60 years of age). The feet are usually involved in early attacks (the 1st metatarsophalangeal joint is involved first in over 50% of cases), although the olecranon bursa and the hands can also be involved (the upper limb is more frequently affected in women). 4 Hospital inpatients not infrequently present with polyarticular attacks. 5 Attacks can be precipitated by intercurrent infections or acute changes in serum uric acid concentration (binge drinking, dehydration, uric acid lowering treatments) and present with severe pain, swelling and redness of the affected area (appearing similar to acute cellulitis). A low-grade pyrexia is often found but the patient is usually systemically well (unless an intercurrent infection has triggered the attack). Tophi (caused by MSUM microcrystal deposition in the skin) are occasionally seen overlying the affected area (tophi overyling involved distal interphal aneal joints of the fingers are shown in Fig 1) , in the pinna of the ear or over areas such as the olecranon bursa. The affected joint/joints will be warm, markedly tender and erythematous -septic arthritis and crystal arthritides, unlike other inflammatory arthropathies, are associated with overlying erythema.
Initially, attacks are generally short lived and self-limiting (characteristically lasting ca 1 week). There are frequently prolonged, symptom-free intercritical
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Clinical Medicine The victim goes to bed and sleeps in good health. About two o'clock in the morning he is awakened by a severe pain in the great toe; more rarely in the heel, ankle or instep. This pain is like that of a dislocation, and yet the parts feel as if cold water were poured over them. Then follow chills and shivers and a little fever. Now it is a violent stretching and tearing of the ligaments -now it is a gnawing pain and now a pressure and tightening … it cannot bear the weight of bedclothes, nor the jar of a person walking in the room. The night is passed in torture, sleeplessness, turning of the part affected, and perpetual change of posture; the tossing about of the body being as incessant as the pain of the tortured joint.
Gout
Consider gout in any acute monoarthritis, not just arthritis involving the great toe
Uric acid levels are unreliable during acute attacks
Synovial fluid analysis is the key to diagnosis and enables exclusion of septic arthritis
Colchicine is best used as prophylaxis rather than for acute treatment of gout periods. If untreated, the frequency of attacks increases, although the severity of individual attacks may decrease. At this later stage symptoms frequently do not entirely resolve between attacks and tophi may develop.
Diagnosis
The diagnosis can usually be made from the history and examination if there is 1st metatarsophalangeal joint involvement, but exclusion of septic arthritis is paramount in the context of an acute monoarthritis. Identification of MSUM microcrystals in a joint aspirate should be attempted whenever there is diagnostic doubt. Aspirated synovial fluid (usually cloudy in appearance) should be sent for crystal analysis as well as for microbiology. MSUM microcrystals are negatively birefringent and needle shaped (Fig 2) when viewed under compensated polarised light, the gold standard for the diagnosis of gout.
Other investigations can be unhelpful in differentiating acute gout from septic arthritis. Neutrophil leucocytosis and elevated C-reactive protein (CRP)/erythrocyte sedimentation rate (ESR) are found in both septic and crystal arthritis and radiographs are usually normal. Uric acid levels are unreliable in acute attacks -a drop in uric acid levels frequently accompanies an attack. 6 
Treatment
Guidelines for the general management of the acute hot joint have been published by the British Society for Rheumatology. 7 The specific management of gout is threefold:
• treatment of the acute attack • prophylaxis against future attacks • reduction of serum uric acid levels.
The acute attack. Acute attacks can generally be managed with early non-steroidal anti-inflammatory drugs (NSAIDs) until the symptoms resolve (there is little to choose between different NSAIDs). If NSAIDs are contraindicated or the patient fails to respond, intra-articular steroid injections, a short course of oral prednisolone (0.5 mg/kg/day for 5 days) or intramuscular depot steroid (eg methylprednisolone acetate 120 mg) can be given. Colchicine at escalating doses is effective, but the gastrointestinal (GI) side effects are significant and the experience frequently puts patients off taking colchicine as prophylaxis (see below). The author's practice is to use alternative options in the acute setting.
Prophylaxis against future attacks. Colchicine (600 µg bd), a drug that inhibits neutrophil microtubule formation, reduces both the frequency and severity of attacks of gout. 8 but a dose reduction can be helpful if there is GI upset. (The published trial 8 used colchicine 600 µg bd; only 500 µg tablets are available in the UK, so 500 µg bd or tds should be prescribed.)
Reduction of serum uric acid levels.
Dietary modification with reduced intake of purine rich foods and alcohol (Table l) should usually be tried before long-term drug therapy. If insulin resistance is a possibility, reduction in total calorie intake should also be advised. 9 Allopurinol, a xanthine oxidase inhibitor that reduces endogenous uric acid production, is generally the first-line pharmacological treatment to reduce serum uric acid levels. It is usually prescribed when more than two attacks occur in any six-month period (with hyperuricaemia) or in patients with tophi or chronic arthritis. Acute changes in uric acid concentrations during treatment initiation can prolong an acute attack or precipitate a flare. This can be reduced by delaying treatment until an acute attack has settled, then starting allopurinol at 100 mg/day with colchicine or NSAID prophylaxis. Allopurinol should then be increased by 100 mg/month (maximum 900 mg, but adjusted according to the creatinine clearance) until the uric acid level is below 0.35 mmol/l (Table 2) . 10, 11 Prophylaxis can be discontinued then or after six months' treatment.
If allopurinol is not tolerated, probenecid or sulphinpyrazone (uricosuric agents) are alternatives, but are generally used second-line and require caution in their use particularly in those with renal impairment.
Calcium pyrophosphate dihydrate arthropathy and pseudogout
Introduction and clinical features
CPPD microcrystals are radio-opaque so, unlike MSUM microcrystals, can be seen deposited in the articular cartilage as chondrocalcinosis on plain radiographs (Fig 3) . Predisposing conditions for CPPD microcrystal formation are shown in Table 3 and should be investigated in younger patients. CPPD microcrystals can cause a spectrum of arthropathies: 1 Chondrocalcinosis without active synovitis can be considered as a variant of nodal osteoarthritis 12 and managed identically to conventional osteoarthritis. 13 (Fig 4) causes intermittent severe neck pain, fever and elevated inflammatory markers which may be mistaken for giant cell arteritis, meningitis or malignancy. 15 
Diagnosis
Diagnosis of pseudogout generally requires exclusion of septic arthritis. The synovial fluid is frequently cloudy and blood stained and aspiration often relieves symptoms. Identification of positively birefringent, rhomboid shaped microcystals (Fig 2) with compensated polarised light microscopy is the gold standard for diagnosis of all CPPD arthropathy, although CPPD microcrystals are more difficult to identify than MSUM crystals. 16 Mild neutrophil leucocytosis and elevated CRP/ESR are usually found in acute pseudogout, whilst chronic CPPD arthritis is characterised by an elevated CRP/ESR with a negative rheumatoid factor. Radiographs may show chondrocalcinosis of the articular cartilage of the knee (Fig 3) or triangular fibrocartilage of the wrist and can be helpful in diagnosis. 
Clinical Medicine
Treatment
If there is a predisposing cause for CPPD arthropathy (Table 3 ) this should be appropriately treated. Acute pseudogout should be managed with NSAIDs or oral, intramuscular or intra-articular steroids in the same way as for gout.
Empiric treatment with low-dose oral steroids or regular colchicine (see gout prophylaxis above) is frequently considered for recurrent pseudogout or chronic CPPD arthropathy, although these therapies are not supported by any evidence base.
Unlike gout, there are no specific dietary interventions or drug therapies to facilitate resorption of the CPPD microcrystals. Clinical Medicine 
